The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Official Title: Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis
Study ID: NCT02862574
Brief Summary: The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Stanford University, Palo Alto, California, United States
Omega Research Consultants, LLC, DeBary, Florida, United States
G. Timothy Kelly, MD, Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Tekton Research, Austin, Texas, United States
Accurate Clinical Research, San Antonio, Texas, United States
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR